When semaglutide was approved for diabetes management, the FDA required cardiovascular outcomes trials to confirm safety. What the trials found was not merely safety — they found cardiovascular benefit. GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) in high-risk populations with a consistency and effect size that has fundamentally changed their clinical positioning from "diabetes drug" to "cardiovascular drug that also manages diabetes and obesity."
The SELECT trial (2023) was the pivotal expansion: it showed that semaglutide reduced cardiovascular events by 20% in non-diabetic patients with obesity and established cardiovascular disease — proving the cardiovascular benefit exists beyond the diabetic population and is not solely mediated by glucose lowering.
Design: n=17,604 adults with BMI ≥27 and established cardiovascular disease but WITHOUT diabetes. Randomized to semaglutide 2.4mg (Wegovy dose) or placebo for a mean 3.3 years.
Primary endpoint: First occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3-point MACE).
Result: Semaglutide reduced 3-point MACE by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001). Heart failure hospitalization was reduced by 18%. All-cause mortality was reduced by 19%. The effect emerged within 3–6 months and continued to diverge throughout the trial — it was not explained by the weight loss magnitude alone, suggesting direct cardiac effects.
Why it matters: This was the first large RCT proving cardiovascular benefit of a GLP-1 drug in people without diabetes. It directly supports prescribing semaglutide for cardiovascular risk reduction in obese patients independent of glucose control goals.
n=9,340, type 2 diabetes with high cardiovascular risk, mean 3.8 years. Liraglutide (Victoza) reduced 3-point MACE by 13% overall, with cardiovascular death specifically reduced by 22% and all-cause mortality by 15%. The LEADER trial was the first to establish class-wide cardiovascular benefit for GLP-1 agonists and shifted diabetes treatment guidelines to prioritize GLP-1 drugs in patients with cardiovascular disease.
n=3,297, type 2 diabetes with high cardiovascular risk, 2 years. SUSTAIN-6 showed 26% reduction in MACE with weekly injectable semaglutide at 0.5mg or 1mg doses — doses lower than the 2.4mg used in SELECT. Stroke reduction was the dominant effect (39% reduction). This trial triggered the cardiovascular risk indication for Ozempic in the US.
GLP-1 receptors (GLP-1R) are expressed on cardiac myocytes, sinoatrial node cells, coronary vascular smooth muscle, and endothelial cells. Direct activation of GLP-1R in heart tissue produces: improved cardiac energy substrate utilization (glucose uptake in cardiomyocytes increases), reduced ischemia-reperfusion injury in animal models, anti-inflammatory effects on cardiac macrophages, and improved endothelial function in coronary vessels. These effects occur independently of and additive to weight loss and glucose lowering.
GLP-1 agonists reduce circulating inflammatory markers (CRP, IL-6, TNF-α) beyond what weight loss alone explains. In animal atherosclerosis models, GLP-1 drugs reduce foam cell formation, macrophage infiltration into arterial walls, and plaque progression. Human intravascular ultrasound studies show coronary plaque stabilization at 12 months in patients on liraglutide. The cardiovascular death reduction in trials appears earlier than the atherosclerosis regression timeline — suggesting additional acute cardioprotective mechanisms, possibly via direct cardiac receptor activation.
STEP-HFpEF trial (2023): semaglutide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity — without diabetes — showed 21% reduction in a composite of worsening heart failure events and cardiovascular death, plus dramatic improvements in symptoms, exercise tolerance, and quality of life. HFpEF is a condition with historically very limited treatment options; this was a clinically meaningful advance. SELECT also showed 18% reduction in heart failure hospitalizations. The mechanism in heart failure appears to be partly weight-dependent (reduced cardiac filling pressure) and partly direct anti-inflammatory.
The clinical bottom line: For patients with obesity and established cardiovascular disease — prior heart attack, stroke, peripheral artery disease, or heart failure — GLP-1 receptor agonists now have Level A evidence for cardiovascular risk reduction. This is no longer a "nice side effect" of a diabetes drug. It is the primary indication for a significant number of cardiologically complex patients, and cardiovascular societies have updated their guidelines accordingly.